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Abstract: Due to the lack of approved vaccines against human leishmaniasis and the limitations of
the current chemotherapy inducing side effects and drug resistance, development of new, effective
chemotherapeutic agents is essential. This study describes the synthesis of a series of novel
oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using
an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite
arginase. Top hits were further screened versus human arginase and finally against an anti-target
battery to tag their possible interactions with proteins essential for the metabolism and clearance
of many substances. Eight candidate compounds were selected for further experimental testing.
The results show measurable in vitro anti-leishmanial activity for three compounds. One compound
with an IC50 value of 2.18 µM on Leishmania donovani intramacrophage amastigotes is clearly better
positioned than the others as an interesting molecular template for further development of new
anti-leishmanial agents.
Keywords: Leishmania; arginase; in silico; anti-target; in vitro; anti-leishmanial inhibitors; anti-target
1. Introduction
The leishmaniases are a group of diseases caused by the trypanosomatid protozoan parasite of
the genus Leishmania through the bite of infected phlebotomine sandflies, endemic to 97 countries in
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parts of the tropics, subtropics, and in Southern Europe [1]. An estimated 700,000 to 1 million new
cases of leishmaniases and 20,000–30,000 deaths occur annually. In 2017, 94% of new cases reported
to the WHO occurred in seven countries: Brazil, Ethiopia, India, Kenya, Somalia, South Sudan,
and Sudan [2]. The three main clinical syndromes of leishmaniasis include cutaneous leishmaniasis
(CL), muco-cutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL) [3].
Leishmaniasis is one of the most neglected diseases in terms of drug development [4,5]. Without
any effective vaccine against leishmaniasis in humans at present, the control of these parasites relies
solely on chemotherapy [6]. The current chemotherapies suffer from several drawbacks due to toxicity,
long-term treatment, severe adverse effects, high cost, invasive administration routes, low effectiveness,
and commonly, drug resistance [4,7,8]. Therefore, there is an urgent need for novel compounds with
substantial antileishmanial effect and low toxicity to the host.
Leishmania and all members of the Trypanosomatidae family depend on polyamines (PA) for growth
and survival [9,10]. The first enzyme involved in PA biosynthesis that hydrolyses arginine into
ornithine and urea is arginase [11]. Arginase inhibition can lead to oxidative stress in parasite cells
owing to a deficiency in trypanothione production that neutralizes reactive macrophage-derived
oxygen and nitrogen species [12], consequently leading to infection control [13]. Arginase is important
for parasite survival: deleting the arginase gene is auxotrophic for polyamines [14]. Being arginase
distinct from the mammalian target [11] and absolute necessity of the enzyme for survival of the
pathogen, it represents a key parasite drug target [15].
Oxadiazoles have been reported as potent anti-leishmanial agents [16,17]. Potent antimicrobial
and anti-leishmanial activity are also documented for indolizine-containing compounds [18,19].
The MetIDB database was screened in previous work with in silico procedures and ten promising
flavonoids were proposed as anti-leishmanial candidates [20]. In this study, a series of novel oxadiazoles
and indolizine containing compounds were synthesized, screened in silico with the Electron Ion
Interaction Potential/Average Quasi Valence Number (EIIP/AQVN) filter, followed by ligand-based
virtual screening and molecular docking to Leishmania arginase. In addition, the top hits were virtually
screened against human arginase and anti-targets. The best selected candidates for anti-leishmanial
compounds were subjected to experimental testing. The experimental results show measurable in vitro
anti-leishmanial activity for three compounds.
2. Results
2.1. Chemistry
2.1.1. Synthesis of 1,2,4-Oxadiazoles
N-acylhydrazones are important and versatile scaffolds. They can be obtained by conventional [21] or
non-conventional methods [22,23]. They can be considered either as final products with important
biological properties or stable intermediates in the design and construction of other motifs like
1,2,4-oxadiazoles. In our hands, as N-acylhydrazones 1–5 were prepared on an automated platform,
we conducted synthesis by refluxing an equimolar mixture of hydrazide and aldehyde in ethanol
with a catalytic amount of hydrochloric acid (Scheme 1). Purifications by filtration of the solid
compounds were parallelized and we were able to isolate about 200 compounds in four batches.
The five compounds used in this work are shown in Table 1.Molecules 2019, 24, x FOR PEER REVIEW 3 of 18 
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Table 1. Isolated acylhydrazones.
Compound Hydrazide Aldehyde Yield (%) Purity 1 (%)
1
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1 Determined by Liquid Chromatography/Mass Spectrometry (LC/MS).
1,2,4-Oxadiazoles can be considered as one of the most important 5-membered heteroaromatic
rings found in many pharmaceutical compounds. Among the various synthetic approaches reported
in the literature [24], one concerns reaction under conventional or non-conventional methods of
amidoximes with suitably activated acid derivatives [25].
Synthesis of the 3-[3,4-(methylenedioxy)phenyl)]-5-(methoxy ethyl)-1,2,4-oxadiazole 8 as
achieved in two steps and 90% total yield by the reaction of 3,4-(met ylenedioxy)benzonitrile with
hydroxylamine to afford quantitatively amidoxime 6 followed by the reaction with methoxyacetyl
chloride under microwave irradiation (Scheme 2). This compound was prepared during a small
molecule library synthesis program, and the protocols established to allow the automatio and the
parallelization of reactions. The first step of the rocedure was applied to 3-nitrobenzonitrile, affording
also in quantitative yield the corresponding 3-nitrobenzamidoxime.
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2.1.2. Synthesis of Indolizines
The 1,3-dipolar cycloaddition reaction of azomethine ylide containing nitrogen in a 6-membered
ring such as pyridine and isoquinoline was applied for the synthesis of the target compounds. In that
Molecules 2019, 24, 1282 4 of 16
respect, 1-((5-nitro-1H-benzo[d]imidazol-2-yl)methyl)pyridin-1-ium chloride 9 and 2-((5-nitro-1H-
benzo[d]imidazol-2-yl)methyl)isoquinolin-2-ium chloride 10(2), (Scheme 3), which were prepared
from the reaction of pyridine/isoquinoline with 2-(chloromethyl)-5-nitro-1H- benzo[d]imidazole
(Scheme 3), as described previously [26,27], undergo a dehydrohalogenation reaction in the presence
of triethylamine in chloroform to give the corresponding pyridinium 9/isoquinolinium 10 ylide in 75%
and 95% yield, respectively. The reaction of the latter (Scheme 4) with DMAD or methyl propiolate at
room temperature and overnight afforded, after workup and column chromatography, the indolizine
11 (25% yield), and benzindolizines 12 and 13 (28% and 27%, respectively). The obtained compounds
were fully characterized by 1H, 13C NMR, mass spectra, and IR.
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2.2. Virtual Screening
2.2.1. EIIP Filtering
We used the previously developed average quasi valence number/electron ion interaction
potential (EIIP/AQVN) criteria for selection of Leishmania arginase compounds [20].
2.2.2. 3D QSAR Filtering
39 molecules were obtained after filtering with EIIP criteria and were subjected to prediction
of their activity using the above described arginase 3D-quantitative structure-activity relationship
(3D-QSAR) model. The two criteria for selection were: (1) partial least square (PLS) scores in the
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vicinity of compounds from the model (Figure 1); and (2) best ranking by predicted IC50 values.
This filtering gave 10 candidates that were used for docking into the Leishmania arginase structure
model, human arginase crystal structure, and off-target (anti-target) affinity calculation.
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results i i , the experiment showed significant activity of six compounds. However,
due to their toxicity, only one candidate, c mpound 2, is acceptable thank to its selectivity index (SI,
CC50 for macrophage/IC50 f r promastigotes)≥ 2, with an IC50 value on intramacroph ge amastigotes
< 5 µM. T e highest ranked docking conformation of this compound in th Leishm nia arginase model
is presented in Figure 2.
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Table 2. Compounds selected from QSAR PLS scores, with calculated EIIP descriptor values, predicted activity, docking scores, and experimental data.
No Code AQVN EIIP Structure Pred.pIC50
Autodock Score
(kcal/mol)
Leishmania
Arginase
Autodock Score
(kcal/mol)
Human
Arginase
Leishmania
donovani LV9 axenic
Amastigotes Forms
IC50 ± SD (µM)
Leishmania donovani
Intramacrophage
Amastigotes Forms
IC50 ± SD (µM)
Toxicity on RAW
264.7 Macrophages
CC50 ± SD (µM)
17 1 3.28 0.125
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2.2.4. Anti-Target Interaction Matrix
The top eight compounds from the filtering were then assessed against the anti-target battery.
The results of the docking of all the final compounds against the battery of five anti-targets are shown
in Figure 3 (full table of docking scores Table 3).
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Figure 3. Interaction matrix between proposed ligands and anti-targets. Color code: black = 1.0;
grey = 0.5, white = 0.0. Columns: PXR = pregnane-X-receptor; SULT = sulfotransferase; CYP 2a6 =
cytochrome P450 cam 2a5; CYP 2c9 = cytochrome P450 cam 2c9; CYP 3a4 = cytochrome P450 cam 3a4;
Total = PXR + SULT + CYP 2a6 + CYP 2c9 + CYP 3a4.
Table 3. In vitro anti-leishmanial activity and cytotoxicity of compounds selected by virtual screening.
Compound
Leishmania donovani LV9
Axenic Amastigotes
IC50 ± SD (µM)
Leishmania donovani LV9
Intramacrophage Amastigotes
IC50 ± SD (µM)
Cytotoxicity on RAW
264.7 Macrophages
CC50 ± SD (µM)
SI = CC50/IC50
Intramacro. Amas.
2 1.09 ± 0.12 2.18 ± 0.12 4.87 ± 0.39 2.2
3 >100 >100 >100 /
4 12.50 ± 0.62 11.22 ± 0.62 16.34 ± 1.42 1.4
5 61.52 ± 5.99 55.22 ± 4.77 > 100 >1.8
1 11.89 ± 1.87 6.25 ± 1.89 13.86 ± 2.11 2.2
8 59.86 ± 6.45 51.26 ± 4.35 >100 >1.9
7 51.21 ± 4.98 47.24 ± 3.12 >100 >2.1
12 >100 >100 >100 /
AmB 0.20 ± 0.08 0.11 ± 0.09 5.36 ± 0.52 48.7
There was broad general agreement between the five anti-targets. None of the compound’s
docking score surpassed that of the threshold for CYP P450 2a6, 2c9, or 3a4, which may be an
indication of the relative size of the ligands. There were more interactions found with the anti-targets
PXR and SULT. Compounds 3 and 5 had the highest combined score of 1.0 for all anti-targets combined,
while most compounds had even lower interactions.
All of the compounds had zero PAINS flags, passed Lipinksi’s rule-of-five, and were predicted
to be soluble or moderately soluble, have high gastrointestinal absorption, and potential (using a
support-vector-machine) CYP 2a6 binding for 2, 3, 4, 5, and CYP 3a4 for 8, according to filters [28].
2.2.5. In vitro Evaluation of Anti-Leishmanial Activity
Finally, we selected eight hit compounds for experimental testing. Since isolated arginase was
not available, the selected compounds were assayed for their in vitro inhibition activity against axenic
amastigote and intramacrophage amastigote forms of Leishmania donovani (Table 3). A broad range of
activities against axenic and intramacrophage amastigotes forms of Leishmania donovani was found
with IC50 values in the range between 1–2 and 55–61 µM. The compounds exhibited similar activities
on both axenic amastigotes and intramacrophage amastigotes. The most potent inhibitors were also
slightly toxic with CC50 values in the range from 4 to 16 µM.
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Regarding structure–activity relationships, the replacement of a thiophene group (compound 4) by
a pyridine group (compound 5) was responsible for a loss of activity by a factor of five and also a strong
reduction of cytotoxicity. Among the tested compounds, one compound, 2, is the most active despite
having a not negligible toxicity. Its chemical structure has two thiophene groups. The replacement
of a thiophene group (compound 2) by a furan group (compound 3) led to a total loss of activity and
cytotoxicity. The replacement of the bromothiophene group (compound 2) by a benzothiazole group
(compound 4) was responsible for a five-fold reduction of the anti-leishmanial activity and four-fold
reduction of cytotoxicity. The replacement of bromothiophene (compound 3) by a methylbenzothiazole
group (compound 1) enhanced both the antileishmanial activity and cytotoxicity. In the phenotypic
based screening, the most promising compound 2 (Table 3) has an IC50 value of 2.18 µM, 20 times
higher than that of amphotericin B, the reference compound. Regarding the selectivity index (SI)
values, compound 2 has an SI of 2, whereas amphotericin B had an SI of 48 against Leishmania axenic
amastigotes. It is also less than four times higher than the reference drug miltefosine (0.31 µM) [29].
The obtained in vitro results clearly require additional pharmacomodulations to reduce the cytotoxicity
and enhance the antileishmanial activity in order to achieve better selectivity index values.
3. Discussion
Inhibition of enzymes of the polyamine–trypanothione metabolism including arginase is
considered as one of the best options for the treatment of Leishmania since many of these enzymes
passed both target validation and chemical validation [10]. In the quest for potential treatment
options against leishmaniasis, increasing interest has been shown for N-acylhydrazone, oxadiazole,
and indolizine containing compounds. These types of compounds targeting arginase represent an
interesting strategy in the search for a new anti-leishmanial treatment.
In our hands, N-acylhydrazones were prepared on an automated platform where reaction
conditions and purifications by filtration of the solid compounds were parallelized for 50 compounds
in each run (about 200 compounds synthetized in four batches). In that respect, reaction conditions
were generalized, and for some of the compounds, yields are not optimum. The same is also true for
the 1,2,4-oxadiazoles where the reaction conditions were chosen in order to prepare a small-molecule
library (150 compounds synthetized). The reaction conditions first afforded the amidoxime compounds
quantitatively, then the reaction with activated acid furnished in good yield the 1,2,4 oxadiazoles,
where one example is used in the current study. Concerning the indolizine compounds, the azomethine
ylide prepared in situ by 1,3 dipolar cycloaddition was chosen. The yields obtained for compounds
11–13 are poor, varying between 25–28% after careful purification. The insolubility of the chloride
salts could be the reason for the low yields. As one of the research programs of the group concerns
1,3 dipolar cycloadditions using this type of ylides, efforts are currently oriented to the synthesis
of indolizine-bearing derivatives under non-conventional methods in order to obtain focused small
libraries of these compounds.
The compounds thus obtained for this study were subsequently screened. The ten selected
compounds from our study with favorable in silico interaction profiles with arginase and against
the anti-targets were favorable for further experimental testing and represent better initial points
than screening compounds at random. Three compounds were found to be active against Leishmania
donovani. One product, compound 2, is better than the others as an interesting molecular template for
further development of new anti-leishmanial agents due to its observed experimental activity against
parasite amastigotes, better selectivity index, and predicted interactions with targets and anti-targets.
Interestingly, the compound that had the best selectivity index, the most promising compound 2, had a
docking score that was approximately 0.8 kcal/mol stronger for the parasite arginase than for human
arginase. This may also indicate that a larger degree of selectivity for a compound may be picked up
by the procedure carried out here.
Considering the mechanism of action of both chemical series, the results obtained in this paper
prompt us to develop further pharmacomodulations in order to diminish the cytotoxicity and enhance
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the anti-leishmanial activity. In any case, despite the level of cytotoxicity of compound 2 being in a
similar range to that of the reference compound AmB, the obtained results justify the determination
of the maximal tolerated dose in mice, and then, the in vivo evaluation of compound 2 on the
L. donovani/BALB/c mice model.
4. Materials and Methods
4.1. Chemistry and Physico-Chemical Analyses
Melting points (m.p.) were determined using a Mettler Toledo MP50 system and were uncorrected.
1H and 13C NMR spectra were recorded in CDCl3 and/or DMSO-d6 using a Bruker AC 300 (1H) or
75 MHz (13C) instruments, except for compounds 1, 2, 4, 6, and 7: 13C-NMR analyses were conducted
with a Bruker AVANCE500 at 298 K (125.75 MHz). Chemical shifts are given in δ parts per million
(ppm) and referenced to external TMS.
Automated syntheses were carried out on an Accelerator SLT-106 workstation from Chemspeed
and microwave assisted reactions on a SWave workstation from Chemspeed equipped with a Biotage
Initiator reactor.
High-resolution mass spectra (MS) were recorded on a GCT Premier Mass Spectrometer (Waters,
MA, USA). Liquid Chromatography/Mass Spectrometry (LC/MS) analyses were performed on an
Autopurif system from Waters (PDA 2996, MS 3100, Pump 2545, MA, USA) with a Gemini-NX column
(5, C18, 110A, 50 × 4.6 mm) from Phenomenex. Analyses were done with 1 mL/min flow and a
gradient of water/acetonitrile containing 0.05% of formic acid (0.0 to 1.0 min: 90/10; 1.0 to 5.0 min:
90/10 to 0/100; 5.0 to 6.5 min: 0/100; 6.5 to 7.0 min: 0/100 to 90/10; 7.0 to 12.0: 90/10) and purities
were determined at 254 nm.
4.1.1. General Procedure for the Automated Synthesis of Compounds 1–5:
Aldehyde (1.00 mmol), hydrazide (1.00 mmol), ethanol (4.0 mL) and 50 µL of aqueous 1M HCl
were added in a 13 mL double jacket reactor from Chemspeed equipped with condenser. The mixture
was shaken at 700 rpm for 4 h at 80 ◦C, then cooled down to 20 ◦C. The precipitate was filtrated and
successively washed with 2 mL of ethanol and 2 mL of ethyl ether to obtain the product.
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N’-[(4-Methyl-2-thiazolyl)methylene]furan-2-carbohydrazide (1): Tan solid, yield: 61%, m.p.: 121–124 ◦C.
LC purity (254 nm): 92%. 1H-NMR (300 MHz, DMSO) δ ppm: 12.22 (s, 1H), 8.62 (s, 1H), 8.00–7.93 (m,
1H), 7.41–7.33 (m, 2H), 6.73 (dd, J = 3.3, 1.5 Hz, 1H), 2.39 (d, J = 0.9 Hz, 3H). 13C-NMR (125.75 MHz,
DMSO) δ ppm: 163.72, 157.80, 154.60, 153.93, 142.57, 116.86, 116.21, 115.16, 112.74, 112.38, 17.14. HRMS
(DCI-CH4, TOF) m/z: [M + H]+ calc. for C10H10N3O2S: 236.0494. Found: 236.0494.
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N’-[(5-Bromo-2-thiophenyl)methylene]thiophene-2-carbohydrazide (2): Light yellow solid, yield: 72%, m.p.:
195–198 ◦C. LC purity (254 nm): 99%. 1H-NMR (300 MHz, DMSO) δ ppm: 11.89 (s, 1H), 8.58 an 8.20
(2 broad singlets, 1H), 8.05–7.93 (m, 1 H), 7.88 (br, 1H), 7.33 (dd, J = 4.5, 0.6 Hz, 1H), 7,27 (d, J = 3.9 Hz,
1H), 7,22 (dd, J = 5.1, 3.9 Hz, 1H). 13C-NMR (125.75 MHz, DMSO) δ ppm: 161.58, 158.40, 142.42, 141.41,
Molecules 2019, 24, 1282 10 of 16
141.24, 138.50, 138.15, 135.65, 135.26, 133.46, 132.47, 131.98, 129.51, 128.60, 127.14, 115.25. HRMS (ES,
TOF) m/z: [M + H]+ calc. for C10H8N2OS2Br: 314.9261. Found: 314.9250.
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N’-[(2-Benzothiazolyl)methylene]thiophene-2-carbohydrazide (4): Light yellow solid, yield: quant., m.p.:
231–234 ◦C. LC purity (254 nm): 99%. 1H-NMR (300 MHz, DMSO) δ ppm: 12.37 (s, 1H), 8.74 and 8.42
(2 br, 1H), 8.20-8.12 (m, 1H), 8.12–7.87 (m, 3H), 7.55 (ddd, J = 14.7, 7.5, 1.5 Hz, 1H), 7.50 (ddd, J = 15.9,
7.5, 1.5 Hz, 1H), 7.27 (dd, J = 4.8, 3.6 Hz, 1H). 13C-NMR (125.75 MHz, DMSO) δ ppm: 165.52, 164.86,
161.86, 158.45, 153.62, 142.24, 138.56, 135.87, 134.63, 130.34, 128.77, 127.17, 127.04, 123.76, 123.00. HRMS
(ES, TOF) m/z: [M + H]+ calc. for C13H10N3OS2: 288.0265. Found: 288.0277.
Molecules 2019, 24, x FOR PEER REVIEW 12 of 18 
 
7.5, 1.5 z, 1 ), 7.27 ( , J = 4.8, 3.6 z, 1 ). 1 -  (125.75 z, S ) δ : 165.52, 164.86, 
161.86, 158.45, 153.62, 142.24, 138.56, 135.87, 134.63, 130.34, 128.77, 127.17, 127.04, 123.76, 123.00. 
HRMS (ES, TOF) m/z: [M + H]+ calc. for C13H10N3OS2: 288.0265. Found: 288.0277. 
 
N’-[(2-Benzothiazolyl)methylene]pyridine-4-carbohydrazide (5): Off-white solid, yield: 70%, m.p.: 234–237 
°C. LC purity (254 nm): 92 %. 1H-NMR (300MHz, DMSO) δ ppm: 12.64 (s, 1H), 8.88–8.81 (m, 2H), 8.79 
(s, 1H), 8.21–8.11 (m, 1H), 8.11–8.03 (m, 1H), 7.92–7.82 (m, 2H), 7.61–7.47 (m, 2H). 13C-NMR (75 MHz, 
DMSO) δ ppm: 164.7, 162.0, 153.1, 150.3, 143.3, 140.1, 134.1, 126.8, 126.7, 123.4, 122.6, 121.7. HRMS 
(ES, TOF) m/z: [M+H]+ calc. for C14H11N4OS: 283.0654. Found: 283.0656. 
4.1.2. General Procedure for the Automated Synthesis of Compounds 6 and 7: 
Nitrile (20.00 mmol), ethanol (30.0 mL) and hydroxylamine (50% in water, 2.0 mL) were added 
in a 75 mL double jacket reactor from Chemspeed equipped with condenser. The mixture was shaken 
at 600 rpm for 5 h at 80 °C, then cooled down to 20 °C. The reaction medium was evaporated under 
reduced pressure and the solid was finally dried overnight in a heated (40 °C) vacuum oven. 
 
3,4-(Methylenedioxy)benzamidoxime (6): White solid, yield: quant. 1H-NMR (300MHz, DMSO) δ ppm: 
9.51 (s, 1H), 7.22–7.16 (m, 2H), 6.93–6.88 (m, 1H), 6.03 (s, 2H), 5.72 (s, 2H). 13C-NMR (125.75 MHz, 
DMSO) δ ppm: 150.98, 148.25, 147.56, 127.87, 119.75, 108.30, 106.17, 101.61. 
 
3-Nitrobenzamidoxime (7): Yellow solid, yield: quant., m.p.: 182-184 °C. 1H-NMR (300MHz, DMSO) δ 
ppm: 9.97 (s, 1H), 8.51 (m, J = 2.1 Hz, 1H), 8.23 (ddd, J = 8.1, 2.4, 0.9 Hz, 1H), 8.12 (ddd, J = 7.8, 1.5, 1.2 
Hz, 1H), 7,68 (t, J = 8.1 Hz, 1H), 6.10 (s, 2H). 13C-NMR (125.75 MHz, DMSO) δ ppm: 149.60, 148.22, 
135.40, 132.04, 130.24, 123.93, 120.40. HRMS (DCI-CH4, TOF) m/z: [M+H]+ calc. for C7H8N3O3: 182.0566. 
Found: 182.0559. 
4.1.3. Procedure for the Synthesis of Compound 8: 
A mixture of 3,4-(methylenedioxy)benzamidoxime (6, 180 mg, 1.00 mmol), acetonitrile (3.0 mL), 
thiethylamine (153 μL, 1.10 mmol) and methoxyacetyl chloride (91 μL, 1.00 mmol) was placed in a 
sealed vial and exposed to microwave irradiation (130 °C, 1 h). The reaction medium was evaporated 
under reduced pressure and the solid was washed with 15 mL of ethyl acetate to give 8 (188 mg, 80% 
yield). 
  
N’-[(2-Benzothiazolyl)methylene]pyridine-4-carbohydrazide (5): Off-white solid, yield: 70%, m.p.:
234–237 ◦C. LC purity (254 nm): 92%. 1H-NMR (300 MHz, DMSO) δ ppm: 12.64 (s, 1H), 8.88–8.81 (m,
2H), 8.79 (s, 1H), 8.21–8.11 (m, 1H), 8.11–8.03 (m, 1H), 7.92–7.82 (m, 2H), 7.61–7.47 (m, 2H). 13C-NMR
(75 MHz, DMSO) δ ppm: 164.7, 162.0, 153.1, 150.3, 143.3, 140.1, 134.1, 126.8, 126.7, 123.4, 122.6, 121.7.
HRMS (ES, TOF) m/z: [M + H]+ calc. for C14H11N4OS: 283.0654. Found: 283.0656.
4.1.2. General Procedure for the Automated Synthesis of Compounds 6 and 7:
Nitrile (20.00 mmol), ethanol (30.0 mL) and hydroxylamine (50% in water, 2.0 mL) were added in
a 75 mL double jacket reactor from Chemspeed equipped with condenser. The mixture was shaken
at 600 rpm for 5 h at 80 ◦C, then cooled down to 20 ◦C. The reaction medium was evaporated under
reduced pressure and the solid was finally dried overnight in a heated (40 ◦C) vacuum oven.
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3,4-(Methylenedioxy)benzamidoxime (6): White solid, yield: quant. 1H-NMR (300MHz, DMSO) δ ppm: 
9.51 (s, 1H), 7.22–7.16 (m, 2H), 6.93–6.88 (m, 1H), 6.03 (s, 2H), 5.72 (s, 2H). 13C-NMR (125.75 MHz, 
DMSO) δ ppm: 150.98, 148.25, 147.56, 127.87, 119.75, 108.30, 106.17, 101.61. 
 
3-Nitrobenzamidoxime (7): Yellow solid, yield: quant., m.p.: 182-184 °C. 1H-NMR (300MHz, DMSO) δ 
ppm: 9.97 (s, 1H), 8.51 (m, J = 2.1 Hz, 1H), 8.23 (ddd, J = 8.1, 2.4, 0.9 Hz, 1H), 8.12 (ddd, J = 7.8, 1.5, 1.2 
Hz, 1H), 7,68 (t, J = 8.1 Hz, 1H), 6.10 (s, 2H). 13C-NMR (125.75 MHz, DMSO) δ ppm: 149.60, 148.22, 
135.40, 132.04, 130.24, 123.93, 120.40. HRMS (DCI-CH4, TOF) m/z: [M+H]+ calc. for C7H8N3O3: 182.0566. 
Found: 182.0559. 
4.1.3. Procedure for the Synthesis of Compound 8: 
A mixture of 3,4-(methylenedioxy)benzamidoxime (6, 180 mg, 1.00 mmol), acetonitrile (3.0 mL), 
thiethylamine (153 μL, 1.10 mmol) and methoxyacetyl chloride (91 μL, 1.00 mmol) was placed in a 
sealed vial and exposed to microwave irradiation (130 °C, 1 h). The reaction medium was evaporated 
under reduced pressure and the solid was washed with 15 mL of ethyl acetate to give 8 (188 mg, 80% 
yield). 
  
3,4-(Methylenedioxy)benzamidoxime (6): White solid, yield: quant. 1H-NMR (300 MHz, DMSO) δ ppm:
9.51 (s, 1H), 7.22–7.16 (m, 2H), 6.93–6.88 (m, 1H), 6.03 (s, 2H), 5.72 (s, 2H). 13C-NMR (125.75 MHz,
DMSO) δ ppm: 150.98, 148.25, 147.56, 127.87, 119.75, 108.30, 106.17, 101.61.
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3-Nitrobenzamidoxime (7): Yellow solid, yield: quant., m.p.: 182-184 ◦C. 1H-NMR (300 MHz, DMSO) δ
ppm: 9.97 (s, 1H), 8.51 (m, J = 2.1 Hz, 1H), 8.23 (ddd, J = 8.1, 2.4, 0.9 Hz, 1H), 8.12 (ddd, J = 7.8, 1.5,
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135.40, 132.04, 130.24, 123.93, 120.40. HRMS (DCI-CH4, TOF) m/z: [M + H]+ calc. for C7H8N3O3:
182.0566. Found: 182.0559.
4.1.3. Procedure for the Synthesis of Compound 8:
A mixture of 3,4-(methylenedioxy)benzamidoxime (6, 180 mg, 1.00 mmol), acetonitrile (3.0 mL),
thiethylamine (153 µL, 1.10 mmol) and methoxyacetyl chloride (91 µL, 1.00 mmol) was placed in a
sealed vial and exposed to microwave irradiation (130 ◦C, 1 h). The reaction medium was evaporated
under reduced pressure and the solid was washed with 15 mL of ethyl acetate to give 8 (188 mg,
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MHz, DMSO) δ ppm: 176.5, 167.2, 150.1, 148.0, 122.1, 119.6, 109.0, 106.6, 101.9, 64.4, 58.8. HRMS (DCI-
CH4, TOF) m/z: [M + H]+ calc. for C11H11N2O4: 235.0719. Found: 235.0712. 
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salt (1 mmol, 1.0 eq.) and alkyne (1.1 mmol, 1.1 eq.) in chloroform was stirred at 0 °C. Triethylamine 
(1.3 mmol, 1.3 eq.) was added dropwise and the mixture was further stirred at room temperature for 
24 h. The reaction medium was evaporated under reduced pressure and the obtained residue was 
purified by flash chromatography. 
99 mg of compound 11 were obtained (25% yield). 
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J = 2.1 Hz, H4′), 8.32–8.18 (m, H6′ + H8), 7.59 (d, J = 8.8 Hz, H7′), 7.38 (dd, J = 9.0, 6.7 Hz, H7), 7.11 (dd, 
J = 7.2, 6.7 Hz, H6), 4.08 (s, 3CH3), 4.00 (s, 3CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 169.2, 163.7, 148.2, 
147.5, 147.3, 143.9, 142.6, 137.0, 173.0, 131.9, 128.4, 126.1, 119.3, 119.0, 115.2, 110.9, 107.9, 53.6, 51.8. 
HRMS (ES, TOF) m/z: [M + H]+ calc. for C19H14N4O6: 395.0992. Found: 395.0988. IR (ATR) (cm−1): 3347, 
3117, 2954, 1716, 1702, 1503, 1215, 749. 
125 mg of compound 12 were obtained (28% yield). 
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°C. Rf: 0.6 EP/THF (1:4 v/v). 1H-NMR (300MHz, CDCl3) δ ppm: 11.75 (s, NH), 8.98 (d, J = 7.5 Hz, H5), 
8.59 (s, H4′), 8.35–8.26 (m, H10), 8.17 (d, J = 8.9 Hz, H6′), 7.86-7.83 (m, H7+H7′), 7.65-7.62 (m, H8+H9), 
7.33 (d, J = 7.5 Hz, H6), 4.00 (s, CH3), 3.85 (s, CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 166.9 (CO), 
164.1 (CO), 146.9 (C5′), 143.4 (C2), 129.0 (CH8 + CH9), 128.9 (C11), 128.7 (C), 128.2 (CH7), 123.9 (C), 
123.9 (CH10), 123.8 (CH5), 119.3 (C), 118.7 (CH6′), 117.5 (C3), 115.4 (CH7′), 115.3 (CH6), 113.1 (CH4′), 
111.0 (C), 53.3 (CH3), 53.0 (CH3). HRMS (ES, TOF) m/z: [M + H]+ calc. for C23H17N4O6: 445.1148. Found: 
445.1127. IR (ATR) (cm−1): 3399, 3109, 2990, 1727, 1686, 1519, 1340, 1210, 734. 
  
3-[3,4-(Methylenedioxy)phenyl)]-5-(methoxymethyl)-1,2,4-oxadiazole (8): Light tan solid, m.p.: 56–57 ◦C.
LC purity (254 nm): 98%. 1H-NMR (300 MHz, DMSO) δ ppm: 7.58 (dd, J = 8.1, 1.8 Hz, 1H), 7.45
(dd, J = 1.5, 0.3 Hz, 1H), 7.09 (dd, J = 8.1, 0.3 Hz, 1H), 6.14 (s, 2H), 4.80 (s, 2H), 3.42 (s, 3H). 13C-NMR
(75 MHz, DMSO) δ ppm: 176.5, 167.2, 150.1, 148.0, 122.1, 119.6, 109.0, 106.6, 101.9, 64.4, 58.8. HRMS
(DCI-CH4, TOF) m/z: [M + H]+ calc. for C11H11N2O4: 235.0719. Found: 235.0712.
4.1.4. General Procedure for the Synthesis of Compounds 11–13:
Compounds 1-((5-nitro-1H-benzo[d]imidazol-2-yl)methyl)pyridin-1-ium chloride 9 and
2-((5-nitro-1H-benzo[d]imidazol-2-yl)methyl)isoquinolin-2-ium chloride 10 were prepared as
previously reported and gave the same experimental characteristics. A mixture of pyridinium/
isoquinolinium salt (1 mmol, 1.0 eq.) and alkyne (1.1 mmol, 1.1 eq.) in chloroform was stirred at 0 ◦C.
Triethylamine (1.3 mmol, 1.3 eq.) was added dropwise and the mixture was further stirred at room
temperature for 24 h. The reaction medium was evaporated under reduced pressure and the obtained
residue was purified by flash chromatography.
99 mg of compound 11 were obtained (25% yield).
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Dimethyl 3-(5-nitro-1H-benzo[d]imidazol-2-yl)indolizine-1,2-dicarboxylate (11): m.p.: 234 ◦C. Rf: 0.6
EP/EtOAc (7:3 v/v). 1H-NMR (300 MHz, CDCl3) δ ppm: 11.65 (s, 1H), 10.30 (d, J = 7.2, Hz, H5), 8.72
(d, J = 2.1 Hz, H4′), 8.32–8.18 (m, H6′ + H8), 7.59 (d, J = 8.8 Hz, H7′), 7.38 (dd, J = 9.0, 6.7 Hz, H7), 7.11
(dd, J = 7.2, 6.7 Hz, H6), 4.08 (s, 3CH3), 4.00 (s, 3CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 169.2, 163.7,
148.2, 147.5, 147.3, 143.9, 142.6, 137.0, 173.0, 131.9, 128.4, 126.1, 119.3, 119.0, 115.2, 110.9, 107.9, 53.6, 51.8.
HRMS (ES, TOF) m/z: [M + H]+ calc. for C19H14N4O6: 395.0992. Found: 395.0988. IR (ATR) (cm−1):
3347, 3117, 2954, 1716, 1702, 1503, 1215, 749.
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125 mg of compound 12 were obtained (28% yield).
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7.33 (d, J = 7.5 Hz, H6), 4.00 (s, CH3), 3.85 (s, CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 166.9 (CO), 
164.1 (CO), 146.9 (C5′), 143.4 (C2), 129.0 (CH8 + CH9), 128.9 (C11), 128.7 (C), 128.2 (CH7), 123.9 (C), 
123.9 (CH10), 123.8 (CH5), 119.3 (C), 118.7 (CH6′), 117.5 (C3), 115.4 (CH7′), 115.3 (CH6), 113.1 (CH4′), 
111.0 (C), 53.3 (CH3), 53.0 (CH3). HRMS (ES, TOF) m/z: [M + H]+ calc. for C23H17N4O6: 445.1148. Found: 
445.1127. IR (ATR) (cm−1): 3399, 3109, 2990, 1727, 1686, 1519, 1340, 1210, 734. 
  
Dimethyl 3-(5-nitro-1H-benzo[d]imidazol-2-yl)pyrrolo[2,1-a]isoquinoline-1,2-dicarboxylate (12): m.p.:162 ◦C.
Rf: 0.6 EP/THF (1:4 v/v). 1H-NMR (300 MHz, CDCl3) δ ppm: 11.75 (s, NH), 8.98 (d, J = 7.5 Hz, H5),
8.59 (s, H4′), 8.35–8.26 (m, H10), 8.17 (d, J = 8.9 Hz, H6′), 7.86-7.83 (m, H7+H7′), 7.65-7.62 (m, H8+H9),
7.33 (d, J = 7.5 Hz, H6), 4.00 (s, CH3), 3.85 (s, CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 166.9 (CO),
164.1 (CO), 146.9 (C5′), 143.4 (C2), 129.0 (CH8 + CH9), 128.9 (C11), 128.7 (C), 128.2 (CH7), 123.9 (C),
123.9 (CH10), 123.8 (CH5), 119.3 (C), 118.7 (CH6′), 117.5 (C3), 115.4 (CH7′), 115.3 (CH6), 113.1 (CH4′),
111.0 (C), 53.3 (CH3), 53.0 (CH3). HRMS (ES, TOF) m/z: [M + H]+ calc. for C23H17N4O6: 445.1148.
Found: 445.1127. IR (ATR) (cm−1): 3399, 3109, 2990, 1727, 1686, 1519, 1340, 1210, 734.
195 mg of compound 13 were obtained (27%)
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115.1, 52.1. HRMS (ES, TOF) m/z: [M + H]+ calc. for C21H24N4O4: 387.1067. Found: 387.1070. IR (ATR) 
(cm−1): 2920, 2851, 1708, 1521, 1341, 1202, 760. 
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The source for data was internal libraries of synthetized oxadiazoles and indolizine-containing 
compounds. 
4.3. Virtual Screening 
Starting with a filter based on EIIP/AQVN values and subsequently, 3D QSAR filtering, and 
arginase docking, hit compounds were docked into anti-targets involved in the metabolism of 
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atoms. EIIP values are calculated according to equations 1 and 2 are expressed in Rydberg units (Ry). 
Similarity in AQVN and EIIP values may give a clue on a common therapeutic target, thus 
setting up criteria for virtual screening of molecular libraries for compounds with similar therapeutic 
properties [20]. 
4.3.2. 3D QSAR 
We used our previously reported 3D QSAR model of Leishmania amazonenzis [20]. 
4.4. Arginase 
The crystal structure of Leishmania mexicana with ABH (4iu0.pdb) was used to generate a model 
for L. amazoniensis. Docking was performed with Autodock 4.6.2. The Lamarckian GA method was 
used to perform the conformational search. 
4.5. Anti-Targets 
The docking for the anti-targets was carried out with Glide XP [32] and proteins with resolution 
≤ 2.6 Å (1m13, 2a3r, 1z10, 1og5, 1tqn) [33,34]. The thresholds for determining a strong interaction 
Methyl 3-(5-nitro-1H-benzo[d]imidazol-2-yl)pyrrolo[2,1-a]isoquinoline-1-carboxylate (13): m.p.: 280 ◦C. Rf:
0.4 EP/EtOAc (4:1 v/v). 1H-NMR (300 MHz, CDCl3) δ ppm: 13.60 (s, NH), 10.03 (d, J = 7.5 Hz, H5),
9.78–9.73 (m, H4′), 8.54–8.51 (m, H10), 8.23 (s, H2), 8.14–8.08 (m, H6′), 7.93–7.89 (m, H7′), 7.70–7.63
(m, H7,H8,H9), 7.52 (d, J = 7.5 Hz, H6), 3.93 (s, CH3). 13C-NMR (75 MHz, DMSO) δ ppm: 164.7, 143.1,
139.5, 131.7, 129.5, 129.2, 128.0, 127.5, 127.2, 127.0, 126.1, 125.2, 124.7, 124.5, 120.3, 119.0, 116.4, 115.4,
115.1, 52.1. HRMS (ES, TOF) m/z: [M + H]+ calc. for C21H24N4O4: 387.1067. Found: 387.1070. IR (ATR)
(cm−1): 2920, 2851, 1708, 1521, 1341, 1202, 760.
4.2. Ligands
The source for data was internal libraries of synthetized oxadiazoles and indolizine-containing
compounds.
4.3. Virtual Screening
Starting with a filter based on EIIP/AQVN values and subsequently, 3D QSAR filtering,
and arginase docking, hit compounds were docked into anti-targets involved in the metabolism
of compounds in order to tag their possible interactions.
4.3.1. EIIP/AQVN
V and the EIIP can give indication on long-range biomolecule interaction (over 0.5 nm) [30],
based on the general model pseudopotential [31]
EIIP = 0.25 Z* sin(1.04 pi Z*)/2pi, (1)
where Z* is the average quasi-valence number (AQVN):
Z* =∑m(ni Zi / N), (2)
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where Zi is the valence number of the ith atomic component, ni is the number of atoms of the ith
component, m is the number of atomic components in the molecule, and N is the total number of
atoms. EIIP values are calculated according to equations 1 and 2 are expressed in Rydberg units (Ry).
Similarity in AQVN and EIIP values may give a clue on a common therapeutic target, thus setting
up criteria for virtual screening of molecular libraries for compounds with similar therapeutic
properties [20].
4.3.2. 3D QSAR
We used our previously reported 3D QSAR model of Leishmania amazonenzis [20].
4.4. Arginase
The crystal structure of Leishmania mexicana with ABH (4iu0.pdb) was used to generate a model
for L. amazoniensis. Docking was performed with Autodock 4.6.2. The Lamarckian GA method was
used to perform the conformational search.
4.5. Anti-Targets
The docking for the anti-targets was carried out with Glide XP [32] and proteins with resolution
≤ 2.6 Å (1m13, 2a3r, 1z10, 1og5, 1tqn) [33,34]. The thresholds for determining a strong interaction
were set to −7.7, −6.3, −7.6, −8.7, and −7.5 kcal/mol. An estimate of the binding was changed to
interaction codes:
Score = 0.0 if ∆G − ∆Gref > 0.5, (3)
Score = 0.5 if |∆G − ∆Gref| ≤ 0.5, (4)
Score = 1.0 if ∆G − ∆Gref < −0.5, (5)
where ∆Gref is the docking score of the protein with co-crystallized active reference ligand, and ∆G is
the docking score for a ligand bound to that protein binding site. Shades were then set to white, grey,
and black.
4.6. Biological Evaluation
4.6.1. Cultures for Parasites and Cells
Leishmania donovani promastigotes (MHOM/ET/67/HU3/LV9) were cultured with 5% CO2 in
M199 complete medium containing M199 medium supplemented with 100 µM adenosine, 0.5 mg/L
hemin, 40 mM Hepes pH 7.4 and 10% heat inactivated fetal bovine serum (HIFBS) in the dark at 26 ◦C.
Late log promastigotes diluted at 1 × 106/mL in M199 complete medium acidified at pH 5.5 and
cultured at 37 ◦C with 5% CO2 provided the cultures of axenic amastigotes of L. donovani.
4.6.2. Macrophage
RAW 264.7 macrophages were grown with 5% CO2 in DMEM complete medium containing
Dulbecco’s Modified Eagle’s Medium (DMEM) with 100 U/mL penicillin-streptomycin, and 10%
HIFBS at 37 ◦C.
4.6.3. In Vitro Anti-Leishmanial Compound Testing on Axenic and Intramacrophage Amastigotes:
Previously described protocols [35] were adapted for evaluation of compounds on L. donovani.
For axenic amastigotes, two-fold serial dilutions of the compounds were done in 96-well microplates
with 100 µL of complete medium (see above). Axenic amastigotes were then added to each well at a
density of 106 mL in a 200 µL final volume. After 72 h of incubation with 5% CO2 at 37 ◦C, 20 µL of
resazurin (450 µM) was added to each well and further incubated with 5% CO2 at 37 ◦C for 24 h in
the dark. Resazurin is reduced to resorufin in living cells and can be then monitored by measuring
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OD570nm (resorufin) and OD600nm (resazurin; Lab systems Multiskan MS). Compound activity was
expressed as IC50 (µM). The drug used for reference was Amphotericin B (AmB).
For intramacrophage amastigote testing, RAW 264.7 macrophages were incubated with 5% CO2
at 37 ◦C for 24 h after being plated in 96-well microplates at a density of 2 × 104 cells per well. Axenic
amastigotes were differentiated as described above, centrifuged at 2000 g for 10 min, re-suspended in
DMEM complete medium, and added to each well to reach a 16:1 parasite to macrophage ratio. 24 h
of infection with 5% CO2 at 37 ◦C proceeded, and extracellular parasites were removed. This was
followed by addition to each well of DMEM complete medium (100 µL) containing two-fold serial
dilutions of the compounds from a maximal concentration of 100 µM. The medium was removed
following treatment of 48 h and replaced by Direct PCR Lysis Reagent (100 µL; Euromedex) before 3
freeze-thaw cycles at room temperature, addition of 50 µg/mL proteinase K, and a final incubation at
55 ◦C overnight to allow cell lysis. 10 µL of each cell extract was then added to 40 µL of Direct PCR
Lysis reagent containing Sybr Green I (0.05%; Invitrogen). Mastercycler® realplex (Eppendorf) was
used to monitor DNA fluorescence. Compound activity was expressed as IC50 (µM). The drug used
for reference was Amphotericin B (AmB).
4.6.4. Cytotoxicity Tests
RAW 264.7 macrophages were used for cytotoxicity testing. Cells were plated in 96-well
microplates at a density of 2 × 104 cells per well. Twenty-four hours of incubation with 5% CO2
at 37 ◦C followed, and then the medium was removed and to each well, 100 µL of DMEM complete
medium containing two-fold serial dilutions of the compounds were added. This was followed by 48 h
of incubation with 5% CO2 at 37 ◦C, after which 10 µL of resazurin (450 µM) was added to each well,
and further incubated with 5% CO2, in the dark for 4 h at 37 ◦C. Cell viability was then monitored as
above. Compound cytotoxicity was expressed as CC50 (Cytotoxic Concentration 50%: concentration
inhibiting the macrophages growth by 50%).
5. Conclusions
There is a growing and urgent need for new chemical compounds for the treatment of several
leishmaniases given the lack of vaccines and the side-effects and lack of efficacy of presently-used
chemicals. Four different series of compounds were synthetized and tested as potent anti-leishmanial
compounds. While the indolizine compound does not present good activity, and the aldoxime
and 1,2,4-oxadiazole tested are both equally moderately active, N-acylhydrazones presented much
better activities. Among them, compound 2 is better than the others and could be considered as
an interesting molecular template for further development of new anti-leishmanial agents due to
its observed experimental activity against parasite Leishmania donovani axenic and intramacrophage
amastigotes, better selectivity index, and predicted interactions with targets and anti-targets. It has a
selectivity index of 2.2. Further work may be carried out to improve the toxicity and potency profiles
of these compounds.
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